Logo

Pfizer Collaborates with Dewpoint to Develop Therapies for Rare Form of Muscular Dystrophy

Share this

Pfizer Collaborates with Dewpoint to Develop Therapies for Rare Form of Muscular Dystrophy

Shots:

  • Dewpoint to receive up front payment and up to $239M as research- development & commercial milestones along with royalties on sales of the therapies
  • The companies collaborated for the development of therapies to treat DM1
  • The companies will collaborate their expertise to advance the novel therapeutic solutions addressing the patients’ needs

 ­ Ref: PRNewswire | Image: Business Wire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions